Merck Press Releases

Published on November 16, 2014 - 09:33 GMT

MSD Announces Positive Study Investigating the Use of Pembrolizumab Compared to Chemotherapy in Patients with Ipilimumab-...

ZURICH--(BUSINESS WIRE)--MSD, known as Merck in the United States and Canada, announced today that a pre-specified analysis of investigational data from a pivotal Phase 2 study (KEYNOTE-002) showed pembrolizumab, the company’s anti-PD-1 therapy, …

Distribution channels: Companies

Published on November 11, 2014 - 13:17 GMT

Merck Announces Results from Phase 2 Study of Investigational Chronic Hepatitis C Treatment Grazoprevir/Elbasvir in Genotype 1 ...

BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from a multi-arm Phase 2 clinical trial evaluating grazoprevir/elbasvir (MK-5172/MK-8742, the company’s …

Distribution channels: Companies

Published on November 11, 2014 - 13:09 GMT

Merck Announces Results from Phase 2 Study of Investigational Chronic Hepatitis C Treatment Grazoprevir/Elbasvir in Genotype 1 ...

BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from a multi-arm Phase 2 clinical trial evaluating grazoprevir/elbasvir (MK-5172/MK-8742, the company’s …

Distribution channels: Companies

Published on November 10, 2014 - 00:13 GMT

Interim Data from Proof-of-Concept Study of Merck’s Investigational Hepatitis C Treatment Grazoprevir/Elbasvir in Combination with ...

BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of interim data from the C-SWIFT study exploring the potential of a candidate triple-therapy regimen consisting of the fixed-dose …

Distribution channels: Companies

Published on November 9, 2014 - 23:56 GMT

Interim Data from Proof-of-Concept Study of Merck’s Investigational Hepatitis C Treatment Grazoprevir/Elbasvir in Combination with ...

BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of interim data from the C-SWIFT study exploring the potential of a candidate triple-therapy regimen consisting of the fixed-dose …

Distribution channels: Companies

Published on November 6, 2014 - 14:39 GMT

New Studies Investigating the Use of KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Advanced Melanoma Compared to ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that in November and December, data will be presented for the first time investigating the use of KEYTRUDA® (pembrolizumab) – …

Distribution channels: Companies

Published on November 5, 2014 - 13:39 GMT

Merck Animal Health Provides Update on Zilmax Five-Step Plan, Announces Next Steps

SUMMIT, N.J.--(BUSINESS WIRE)--Merck Animal Health (known outside the United States and Canada as MSD Animal Health) is pleased to announce significant progress in the implementation of its Zilmax Five-Step Plan. With insights from the company’s advisory …

Distribution channels: Companies

Published on November 3, 2014 - 10:15 GMT

Merck Announces Data from 48-Week Phase 2b Study of Investigational HIV Therapy Doravirine (MK-1439) in Treatment-Naive Patients

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from a Phase 2b clinical trial evaluating the safety and efficacy of once-daily oral doravirine, an …

Distribution channels: Companies

Published on November 3, 2014 - 10:05 GMT

Merck Announces Data from 48-Week Phase 2b Study of Investigational HIV Therapy Doravirine (MK-1439) in Treatment-Naive Patients

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from a Phase 2b clinical trial evaluating the safety and efficacy of once-daily oral doravirine, an …

Distribution channels: Companies

Published on October 27, 2014 - 11:08 GMT

Merck Receives FDA Breakthrough Therapy Designation for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to KEYTRUDA® (pembrolizumab), the …

Distribution channels: Companies

Published on October 27, 2014 - 11:08 GMT

Merck Announces Third-Quarter 2014 Financial Results

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2014. Third Quarter Third Quarter $ in millions, except EPS amounts 2014 2013 …

Distribution channels: Companies

Published on October 27, 2014 - 11:02 GMT

Merck Receives FDA Breakthrough Therapy Designation for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to KEYTRUDA® (pembrolizumab), the …

Distribution channels: Companies

Published on October 27, 2014 - 11:02 GMT

Merck Announces Third-Quarter 2014 Financial Results

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2014. Third Quarter Third Quarter $ in millions, except EPS amounts 2014 2013 …

Distribution channels: Companies

Published on October 20, 2014 - 12:18 GMT

US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur’s Investigational Pediatric Hexavalent ...

WHITEHOUSE STATION, N.J. SWIFTWATER, Pa.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT:SAN and NYSE:SNY), announced today that the Biologics License …

Distribution channels: Companies

Published on October 20, 2014 - 12:11 GMT

US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur’s Investigational Pediatric Hexavalent ...

WHITEHOUSE STATION, N.J. SWIFTWATER, Pa.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT:SAN and NYSE:SNY), announced today that the Biologics License …

Distribution channels: Companies

Published on October 15, 2014 - 12:22 GMT

Merck Announces Final Results of Tender Offers for Eight Series of Notes

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck Co., Inc. (“Merck”) (NYSE:MRK), known as MSD outside the United States and Canada, announced today the final results of the previously announced offers to purchase (collectively, the “Offers”) any and all of …

Distribution channels: Companies

Published on October 14, 2014 - 22:53 GMT

Merck Announces Pricing of Tender Offers for Eight Series of Notes

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck Co., Inc. (“Merck”) (NYSE:MRK), known as MSD outside the United States and Canada, announced today the pricing of the previously announced offers to purchase (collectively, the “Offers”) any and all of the …

Distribution channels: Companies

Published on October 8, 2014 - 15:31 GMT

Merck to Present New Data from Clinical Studies Evaluating Investigational Hepatitis C Treatment Grazoprevir/Elbasvir (MK-5172/MK-...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new data from clinical studies of the company’s investigational, oral, once-daily, fixed-dose combination chronic hepatitis …

Distribution channels: Companies

Published on October 8, 2014 - 15:15 GMT

Merck to Present New Data from Clinical Studies Evaluating Investigational Hepatitis C Treatment Grazoprevir/Elbasvir (MK-5172/MK-...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new data from clinical studies of the company’s investigational, oral, once-daily, fixed-dose combination chronic hepatitis …

Distribution channels: Companies

Published on October 6, 2014 - 16:56 GMT

Merck Prices EUR 2.5 Billion Debt Offering

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck Co., Inc. (the “Company”) (NYSE:MRK), known as MSD outside of the United States and Canada, priced today EUR 2.5 billion public offering of three series of Euro-denominated senior unsecured notes ( …

Distribution channels: Companies

Merck Press Releases Distributed by EIN Presswire